CTX-10726 / Compass Therap - LARVOL DELTA

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire) - "CTX-10726 (PD-1 x VEGF-A bispecific antibody): The Phase 1 study has been initiated with clinical data expected in the fourth quarter of 2026....The multi-center study will enroll patients with a prioritized set of solid tumor indications, including patients with locally advanced, unresectable or metastatic renal cell carcinoma, gastroesophageal cancer, hepatocellular carcinoma, and endometrial cancer, in whom standard of care therapies have failed....Initiation of the Phase 2 trial of CTX-471 in patients with tumors expressing NCAM (CD56) is expected in the second half of 2026."

New P2 trial • P1 data • Clear Cell Renal Cell Carcinoma • Endometrial Cancer • Gastroesophageal Cancer • Hepatocellular Cancer • Renal Cell Carcinoma

A Phase 1 Study of the Safety and Tolerability of CTX-10726 (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Compass Therapeutics | Not yet recruiting ➔ Recruiting

dMMR • Enrollment open • First-in-human • MSI-H • Clear Cell Renal Cell Carcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

A Phase 1 Study of the Safety and Tolerability of CTX-10726 (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Compass Therapeutics

dMMR • First-in-human • MSI-H • New P1 trial • Clear Cell Renal Cell Carcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

CTX-10726 (PD-1 x VEGF-A bispecific antibody) (GlobeNewswire) - "CTX-10726 IND-enabling studies continue to progress with IND submission on track for Q4 2025. Initial Phase 1 clinical data for CTX-10726 are expected in H2 2026. CTX-10726 demonstrated superior tumor control compared to ivonescimab in head-to-head studies with a human NSCLC (HCC827) xenograft mouse model, as well as superior PD-1 inhibition in head-to-head studies with a mouse (MC38) model of PD-1 blockade....The preclinical data will be presented this week at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting..."

IND • P1 data • Preclinical • Non Small Cell Lung Cancer

Preclinical development of CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A for the treatment of patients with cancer (SITC 2025) - "In vivo, CTX-10726 outperformed benchmark biosimilar anti-VEGF or PD-1 antibodies in controlling tumor growth across multiple xenograft and syngeneic models.Conclusions CTX-10726 is a potent bispecific antibody that simultaneously inhibits tumor angiogenesis and PD-1-mediated immune suppression and eliminates tumors in preclinical mouse models. CTX-10726 is currently undergoing IND-enabling studies to determine the optimal starting dose for first-in-human trials."

IO biomarker • Preclinical • Cervical Cancer • Endometrial Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • IFNG

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire) - "Successfully completed a pre-IND meeting for CTX-10726 (PD-1 x VEGF-A bispecific antibody), maintaining progress towards expected Q4 2025 IND filing and 2026 clinical data. Advanced the Phase 1 dose-escalation study of CTX-8371 in a post-checkpoint inhibitor patient population to the fourth dosing cohort with no dose-limiting toxicities observed to date; data from this study are expected in the second half of 2025....Phase 2 trial initiation of CTX-471 in patients with tumors expressing NCAM (CD56) is expected in the second half of 2025."

IND • New P2 trial • P1 data • Hodgkin Lymphoma • Melanoma • Non Small Cell Lung Cancer • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire) - "Continued to advance CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards expected year-end 2025 IND filing, with clinical data expected in 2026."

Clinical data • IND • Solid Tumor

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate (GlobeNewswire) - "CTX-10726 (a novel PD-1 x VEGF-A bispecific) is advancing as a new drug candidate after a year of preclinical development, with YE 2025 IND expected."

IND • Oncology